Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Oncternal Therapeutics, Inc. | a16-22203_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 28, 2016
GTx, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
000-50549 |
|
62-1715807 |
|
(State or Other Jurisdiction |
|
(Commission File |
|
(IRS Employer Identification No.) |
|
175 Toyota Plaza |
|
38103 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (901) 523-9700
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On November 28, 2016, GTx, Inc. issued a press release announcing that enobosarm achieved the pre-specified primary efficacy endpoint in the 9 mg dose cohort from patients in both stage 1 and the ongoing stage 2 of its Phase 2 clinical trial in women with advanced, estrogen receptor positive, androgen receptor positive breast cancer.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release issued by GTx, Inc. dated November 28, 2016 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: November 28, 2016 |
GTx, Inc. | |
|
|
| |
|
|
By: |
/s/ Henry P. Doggrell |
|
|
Name: |
Henry P. Doggrell |
|
|
Title: |
Vice President, Chief Legal Officer and Secretary |